Brokerages Set Enovis Co. (NYSE:ENOV) Price Target at $65.86

Shares of Enovis Co. (NYSE:ENOV) have received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $65.86.

Separately, Needham & Company LLC reissued a “buy” rating and set a $65.00 price objective on shares of Enovis in a report on Thursday, November 7th.

Institutional Investors Weigh In On Enovis

A number of institutional investors have recently made changes to their positions in the company. Confluence Investment Management LLC bought a new stake in Enovis during the 4th quarter worth approximately $3,494,000. Chartwell Investment Partners LLC grew its position in Enovis by 25.6% in the third quarter. Chartwell Investment Partners LLC now owns 201,652 shares of the company’s stock worth $8,681,000 after acquiring an additional 41,089 shares in the last quarter. Geode Capital Management LLC boosted its stake in Enovis by 9.5% during the third quarter. Geode Capital Management LLC now owns 921,437 shares of the company’s stock worth $39,678,000 after buying an additional 80,165 shares during the period. UMB Bank n.a. boosted its position in shares of Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock valued at $34,000 after buying an additional 437 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Enovis during the third quarter valued at approximately $1,050,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Trading Down 1.5 %

ENOV opened at $44.09 on Monday. Enovis has a fifty-two week low of $38.27 and a fifty-two week high of $65.03. The firm has a market capitalization of $2.51 billion, a PE ratio of -20.13 and a beta of 1.94. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The company’s 50-day moving average is $45.91 and its 200 day moving average is $44.52.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.11. The business had revenue of $505.22 million during the quarter, compared to the consensus estimate of $504.44 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm’s quarterly revenue was up 21.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.56 EPS. As a group, research analysts predict that Enovis will post 2.79 earnings per share for the current fiscal year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.